☆ 4.8 Meeting Abstract

Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (<= 6 mo or > 6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve

CANCER RESEARCH (2022)

Journal

CANCER RESEARCH

Volume 82, Issue 4, Pages -

Publisher

AMER ASSOC CANCER RESEARCH

DOI: 10.1158/1538-7445.SABCS21-P1-18-08

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (<= 6 mo or > 6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve

Journal

CANCER RESEARCH

Publisher

AMER ASSOC CANCER RESEARCH

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (<= 6 mo or > 6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve

Journal

CANCER RESEARCH

Publisher

AMER ASSOC CANCER RESEARCH

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper